How are you approaching endocrine therapy for patients with metastatic HR+/HER2+ breast cancer in light of enhanced HER2 directed treatment with either T-DXd/pertuzumab or HP/tucatinib?

When would you initiate the endocrine therapy? Will you add palbociclib as per PATINA?